Skip to content

Perioperative Individually Tailored Psychological Intervention in Breast Cancer Surgery

Perioperative Individually Tailored Psychological Intervention in Breast Cancer Patients Improves Psychological Indices and Molecular Biomarkers of Metastasis in Excised Tumors

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07510997
Enrollment
40
Registered
2026-04-06
Start date
2018-01-01
Completion date
2022-12-31
Last updated
2026-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This randomized controlled trial examined whether a perioperative individually tailored psychological intervention can reduce psychological distress and modulate pro-metastatic molecular processes in breast cancer patients undergoing surgery. Forty women with stage I-III breast cancer were randomized to receive either a 6-week individualized psychological intervention or standard nursing care. Primary outcomes included tumor gene expression profiles associated with adrenergic, inflammatory, and metastatic signaling pathways. Secondary outcomes included psychological distress, stress, and resilience measures assessed across multiple perioperative time points.

Interventions

BEHAVIORALIndividually Tailored Perioperative Psychological Intervention

A 6-week individually tailored psychological intervention delivered perioperatively, including six sessions with a trained medical psychologist and bi-weekly phone calls. The intervention targets emotional, cognitive, physiological, and behavioral stress responses, and includes psychoeducation, stress-reduction techniques, coping strategies, and enhancement of social support, based on individual patient needs assessed before surgery.

Standard nursing staff attention (treatment-as-usual) without structured psychological intervention.

Sponsors

Rabin Medical Center
Lead SponsorOTHER
SPARK Israel
CollaboratorUNKNOWN
ICRF, United States
CollaboratorUNKNOWN
IMH, Israel
CollaboratorUNKNOWN
IMS, Israel
CollaboratorUNKNOWN
ISF, Israel
CollaboratorUNKNOWN
Tel Aviv University, Israel
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Women with stage I-III breast cancer * Scheduled for curative surgery * Age 20-80

Exclusion criteria

* Metastatic disease * Neoadjuvant therapy * Other malignancy * Severe psychiatric conditions

Design outcomes

Primary

MeasureTime frameDescription
Tumor gene expression signaturesAt surgery (tumor resection)Transcriptional activity of pro-metastatic, inflammatory, and adrenergic signaling pathways in excised tumors assessed via RNA sequencing.

Secondary

MeasureTime frameDescription
Psychological distress (BSI-18)Baseline (2-3 weeks before surgery), 3-4 weeks after surgery, and 3 months after surgeryPsychological distress assessed using the Brief Symptom Inventory-18 (BSI-18), including Global Severity Index (GSI) and subscales for depression, anxiety, and somatization.
Self-reported stress levelBaseline, 1 day before surgery, 1 day after surgery, 3-4 weeks after surgery, and 3 months after surgerySelf-reported stress level assessed using a 1-100 scale reflecting perceived stress during the previous 24 hours.
Hope (Hope-18)Baseline and 3-4 weeks after surgeryHope assessed using the Hope-18 questionnaire, including intrapersonal, interpersonal, and transpersonal domains.
Perceived social support (MSPSS)Baseline and 3-4 weeks after surgeryPerceived social support assessed using the Multidimensional Scale of Perceived Social Support (MSPSS), including family, friends, and significant others subscales.
Fatigue (SF-36 subscale)Baseline and 3-4 weeks after surgeryFatigue assessed using the fatigue subscale of the Short Form Health Survey (SF-36).

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026